UCB Early-stage Parkinson's efforts tremble
UCB's efforts into the neurodegenerative space prove a tough nut to crack, as a Phase 2a study in early Parkinson's disease missed its primary and secondary endpoints. Oral small molecule minzasolmin was designed to address alpha-synuclein misfolding, one of the hallmarks of Parkinson's, but failed to show efficacy in the ORCHESTRA trial. We currently do not yet have strong hypotheses on the reasons of the failure (mechanism of action/drug/trial-related), but minza represented less than 1% of our sum-of-the-parts, so our € 214 TP and Accumulate rating remains unchanged.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.